Open Access Repository

A review of the role and clinical utility of anti-Ro52/TRIM21 in systemic autoimmunity

Lee, AYS 2017 , 'A review of the role and clinical utility of anti-Ro52/TRIM21 in systemic autoimmunity' , Rheumatology International, vol. 37, no. 8 , pp. 1323-1333 , doi: 10.1007/s00296-017-3718-1.

Full text not available from this repository.

Abstract

Anti-Ro52/tripartite motif-containing 21 (TRIM21) is a ubiquitous antibody found in a number of systemic autoimmune conditions including Sjögren's syndrome, systemic lupus erythematosus and systemic sclerosis, appearing in about half of these patients. Once coupled with its closely related antibody, anti-Ro60 as the anti-SSA antibody, anti-Ro52 is emerging as a unique antibody with direct pathogenic disease involvement and distinct clinical properties. As a result, recent attention has turned to this antibody and its clinical associations and utility. There is a suggestion of anti-Ro52 being associated with more clinical and laboratory markers of disease; however, marked disagreements occur about its association with various clinical entities such as interstitial lung disease and Raynaud's phenomena. Nevertheless, with a relative paucity of studies about these across the systemic autoimmunity paradigm, limited confidence can be invested in these conclusions. Although the antibody holds great potential as a biomarker, further studies examining its clinical utility are needed. This paper will review the mechanisms of Ro52 as an autoantigen and the clinical associations of anti-Ro52 in human autoimmunity.

Item Type: Article
Authors/Creators:Lee, AYS
Keywords: antibody, autoimmunity, Ro52, SSA, TRIM21
Journal or Publication Title: Rheumatology International
Publisher: Springer-Verlag
ISSN: 0172-8172
DOI / ID Number: 10.1007/s00296-017-3718-1
Copyright Information:

© Springer-Verlag Berlin Heidelberg 2017

Item Statistics: View statistics for this item

Actions (login required)

Item Control Page Item Control Page
TOP